To determine if acetylsalicylic acid (ASA) would reduce stroke frequency and mortality in patients with reversible cerebral ischemic attacks.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
Cooperative, double-blind, placebo-controlled, randomized trial of 203 patients at 6 centers.
Patients were randomized to receive treatment of either ASA 1000 mg daily or placebo. Follow-up visits took place every month initially and later at intervals of up to 6 months. Median follow-up period was 25 months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Stroke or death.|
|Secondary||Recurrence of transient ischemic attack, non-fatal myocardial infarction.|